RET and ovarian carcinoma: Lenvatinib, an oral multi-targeted TKI of VEGFR1-3, FGFR, PDGFR-β, RET, and KIT, is the representative TKI clinically targeted in ovarian cancers and has been approved by the FDA in combination with pembrolizumab for microsatellite stable recurrent endometrial cancer in 2019 [83] with a number of ongoing clinical trials (NCT03797326, NCT04781088, NCT04519151, NCT02788708, and NCT05114421) [20].